NASDAQ:NSTG - NanoString Technologies Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $15.10 +0.09 (+0.60 %) (As of 07/16/2018 04:00 PM ET)Previous Close$15.01Today's Range$14.72 - $15.3852-Week Range$5.87 - $16.75Volume233,983 shsAverage Volume204,624 shsMarket Capitalization$386.52 millionP/E Ratio-8.17Dividend YieldN/ABeta0.8 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, protein immune profiling, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, nCounter Vantage 3D, miRNA expression, cancer copy number variation, and other gene expression panels. Further, the company offers nCounter-based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc., as well as the Cancer Therapy Evaluation Program of the National Cancer Institute. The company was founded in 2003 and is headquartered in Seattle, Washington. Receive NSTG News and Ratings via Email Sign-up to receive the latest news and ratings for NSTG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:NSTG CUSIPN/A Webwww.nanostring.com Phone206-378-6266 Debt Debt-to-Equity Ratio1.97 Current Ratio3.29 Quick Ratio2.67 Price-To-Earnings Trailing P/E Ratio-8.17 Forward P/E Ratio-5.47 P/E GrowthN/A Sales & Book Value Annual Sales$114.90 million Price / Sales3.38 Cash FlowN/A Price / CashN/A Book Value$1.58 per share Price / Book9.56 Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-43,560,000.00 Net Margins-36.62% Return on Equity-108.29% Return on Assets-31.72% Miscellaneous Employees467 Outstanding Shares25,750,000Market Cap$386.52 NanoString Technologies (NASDAQ:NSTG) Frequently Asked Questions What is NanoString Technologies' stock symbol? NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG." How were NanoString Technologies' earnings last quarter? NanoString Technologies Inc (NASDAQ:NSTG) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.75) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.01. The biotechnology company had revenue of $23.09 million for the quarter, compared to analysts' expectations of $21.48 million. NanoString Technologies had a negative return on equity of 108.29% and a negative net margin of 36.62%. View NanoString Technologies' Earnings History. When is NanoString Technologies' next earnings date? NanoString Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for NanoString Technologies. What price target have analysts set for NSTG? 4 brokerages have issued 1 year price objectives for NanoString Technologies' stock. Their predictions range from $15.00 to $20.00. On average, they anticipate NanoString Technologies' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price. View Analyst Ratings for NanoString Technologies. What is the consensus analysts' recommendation for NanoString Technologies? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of NanoString Technologies' key competitors? Some companies that are related to NanoString Technologies include Sangamo Therapeutics (SGMO), Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Cellectis (CLLS), DBV Technologies (DBVT), Adaptimmune Therapeutics (ADAP), BAVARIAN NORDIC/S (BVNRY), Coherus Biosciences (CHRS), Heska (HSKA), Autolus Therapeutics (AUTL), La Jolla Pharmaceutical (LJPC) and Avrobio (AVRO). Who are NanoString Technologies' key executives? NanoString Technologies' management team includes the folowing people: Mr. R. Bradley Gray, CEO, Pres & Director (Age 41)Mr. J. Chad Brown, Sr. VP of Sales & Marketing (Age 60)Dr. Joseph M. Beechem, Sr. VP of R&D (Age 60)Mr. K. Thomas Bailey, CFO & Treasurer (Age 49)Dr. Mary Tedd Allen, Sr. VP of Operations (Age 55) Has NanoString Technologies been receiving favorable news coverage? News stories about NSTG stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NanoString Technologies earned a daily sentiment score of 0.09 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.62 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. How do I buy shares of NanoString Technologies? Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NanoString Technologies' stock price today? One share of NSTG stock can currently be purchased for approximately $15.10. How big of a company is NanoString Technologies? NanoString Technologies has a market capitalization of $386.52 million and generates $114.90 million in revenue each year. The biotechnology company earns $-43,560,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. NanoString Technologies employs 467 workers across the globe. How can I contact NanoString Technologies? NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected] MarketBeat Community Rating for NanoString Technologies (NASDAQ NSTG)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 191 (Vote Outperform)Underperform Votes: 168 (Vote Underperform)Total Votes: 359MarketBeat's community ratings are surveys of what our community members think about NanoString Technologies and other stocks. Vote "Outperform" if you believe NSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSTG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?